<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Akt/mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (mTOR) signaling pathway is important for both cell growth and survival </plain></SENT>
<SENT sid="1" pm="."><plain>In particular, an impaired regulation of the Akt/mTOR axis has been strongly implicated in mechanisms related to <z:e sem="disease" ids="C0007621" disease_type="Neoplastic Process" abbrv="">neoplastic transformation</z:e>, through enhancement of cell proliferation and survival </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a group of <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> hematopoietic stem cell disorders characterized by ineffective hematopoiesis and by a high risk of evolution into <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The pathogenesis of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> evolution into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is still unclear, although some recent studies indicate that aberrant activation of survival signaling pathways could be involved </plain></SENT>
<SENT sid="4" pm="."><plain>In this investigation, done by means of immunofluorescent staining, we report an activation of the Akt/mTOR pathway in high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, not only mTOR was activated but also its downstream targets, 4E-binding protein 1 and p70 ribosomal S6 kinase </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment with the selective mTOR inhibitor, <z:chebi fb="0" ids="9168">rapamycin</z:chebi>, significantly increased apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> of CD33(+) (but not CD33(-)) cells from high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="9168">Rapamycin</z:chebi> was ineffective in cells from healthy donors or low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, incubation of high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patient CD34(+) cells with <z:chebi fb="0" ids="9168">rapamycin</z:chebi> decreased the in vitro clonogenic capability of these cells </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, the <z:chebi fb="0" ids="50914">phosphoinositide 3-kinase inhibitor</z:chebi>, LY294002, did not significantly affect the clonogenic activity of high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells </plain></SENT>
<SENT sid="10" pm="."><plain>Taken together, our results indicate that the Akt/mTOR pathway is critical for cell survival and proliferation in high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, this signaling network could become an interesting therapeutic target for treating more advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases </plain></SENT>
</text></document>